Department of Immunology, Medical College of Chinese People's Armed Police Forces, Tianjin, People's Republic of China.
Mol Cell Endocrinol. 2011 Apr 30;337(1-2):43-51. doi: 10.1016/j.mce.2011.01.018. Epub 2011 Feb 2.
Estrogen analogues are promising drugs for postmenopausal osteoporosis, but because of their possible side effects such as increased risk of cancer, estrogens which exert their estrogenic effects selectively on bone are desired. It has been shown that rhein inhibits osteoclast formation and bone resorption activity and has an antitumor role in several types of cancers. Having found that rhein had high affinity for the bone mineral, we synthesized estrone-rhein hybrid compounds and confirmed that one of these hybrid compounds, LC, exhibited a selective profile in the bone and prevented bone loss but had no effect on endometrium growth in ovariectomized rats. However, the mechanisms underlying its actions on human bone cells have not been well defined. Here we show that LC concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-κB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes. Treatment with the ER antagonist ICI 182,780 abrogates the above actions of LC on osteoblast-derived cells. Using small interfering double-stranded RNAs (siRNA) technology, we further demonstrate that the effects of LC on IL-6 production are mediated by both ERα and ERβ but those on OPG and RANKL expression primarily by ERα. Furthermore, we also demonstrate that LC functions at least partially through activation of the classic estrogen response element (ERE) pathway as well as Ras/MEK/ERK and PI3K/Akt signaling. The effect of LC on bone is due to not only its estrogenic activity but also action of its rhein moiety. Also, this compound shows much weaker effect on breast epithelial cell growth than that of estrone. Therefore, using rhein for conjugating compounds is a promising method of effectively targeting estrogens to the bone.
雌激素类似物是治疗绝经后骨质疏松症的有前途的药物,但由于其可能的副作用,如癌症风险增加,因此人们希望具有选择性骨雌激素作用的雌激素。已经表明,大黄素抑制破骨细胞形成和骨吸收活性,并在几种类型的癌症中具有抗肿瘤作用。我们发现大黄素对骨矿物质具有高亲和力,因此合成了雌酮-大黄素混合化合物,并证实其中一种混合化合物 LC 在骨骼中表现出选择性特征,可防止骨质流失,但对去卵巢大鼠的子宫内膜生长没有影响。然而,其对人骨细胞作用的机制尚未得到很好的定义。在这里,我们表明 LC 同时刺激骨保护素 (OPG),并抑制核因子-κB 配体 (RANKL) 和白细胞介素-6 (IL-6) 的产生由含有两种雌激素受体 (ER) 同工型的人成骨细胞 MG-63 细胞产生。用 ER 拮抗剂 ICI 182,780 处理可消除 LC 对成骨细胞衍生细胞的上述作用。使用小干扰双链 RNA (siRNA) 技术,我们进一步证明 LC 对 IL-6 产生的影响是通过 ERα 和 ERβ 介导的,但对 OPG 和 RANKL 表达的影响主要是通过 ERα 介导的。此外,我们还证明 LC 通过经典雌激素反应元件 (ERE) 途径以及 Ras/MEK/ERK 和 PI3K/Akt 信号通路的激活发挥作用。LC 对骨骼的作用不仅与其雌激素活性有关,还与其大黄素部分的作用有关。此外,该化合物对乳腺上皮细胞生长的影响比雌酮弱得多。因此,使用大黄素进行化合物缀合是将雌激素有效靶向骨骼的有前途的方法。